13.58

2.51% -0.35

Pre-market: 13.65 0.07 +0.52%

Amylyx Pharmaceuticals Inc (AMLX)

Overview News Price History Option Chain Financials Discussions Forecast

Amylyx Pharmaceuticals Inc stock is traded at $13.58, with a volume of 818.49K. It is down -2.51% in the last 24 hours and down -22.49% over the past month. Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

Previous Close:

$13.93

Open:

$13.95

24h Volume:

818.49K

Relative Volume:

0.75

Market Cap:

$1.51B

Revenue:

$-665.00K

Net Income/Loss:

$-144.74M

P/E Ratio:

-8.7461

EPS:

-1.5527

Net Cash Flow:

$-123.48M

1W Performance:

+2.22%

1M Performance:

-22.49%

6M Performance:

-7.43%

1Y Performance:

+153.36%

1-Day Range:

$13.57

$14.06

1-Week Range:

$12.44

$14.06

52-Week Range:

$4.64

$18.61

Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile

Name

Amylyx Pharmaceuticals Inc

Sector

Healthcare (1106)

Industry

Drug Manufacturers - Specialty & Generic (86)

Phone

617-682-0917

Address

55 CAMBRIDGE PARKWAY, CAMBRIDGE

Employee

136

Twitter

Next Earnings Date

2026-05-07

Latest SEC Filings

AMLX's Discussions on Twitter

Compare AMLX vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AMLX Amylyx Pharmaceuticals Inc	13.58	1.55B	-665.00K	-144.74M	-123.48M	-1.5527
TAK Takeda Pharmaceutical Co Adr	16.25	52.07B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.29	41.28B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	34.07	39.78B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	81.32	33.57B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	568.43	24.02B	3.17B	1.29B	1.01B	27.09

Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-03-26	Initiated	Stifel	Buy
Jul-10-25	Resumed	Goldman	Buy
Jun-24-25	Initiated	Guggenheim	Buy
Jun-17-25	Initiated	Citigroup	Buy
May-30-25	Initiated	TD Cowen	Buy
Apr-07-25	Upgrade	Mizuho	Neutral → Outperform
Nov-18-24	Upgrade	Robert W. Baird	Neutral → Outperform
Oct-23-24	Upgrade	BofA Securities	Neutral → Buy
Mar-18-24	Downgrade	Mizuho	Buy → Neutral
Mar-11-24	Downgrade	Leerink Partners	Outperform → Market Perform
Mar-11-24	Downgrade	Robert W. Baird	Outperform → Neutral
Mar-08-24	Downgrade	Evercore ISI	Outperform → In-line
Mar-08-24	Downgrade	Goldman	Buy → Neutral
Jan-03-24	Initiated	Robert W. Baird	Outperform
Dec-12-23	Initiated	Deutsche Bank	Buy
Jul-24-23	Upgrade	Goldman	Neutral → Buy
Mar-31-23	Initiated	Mizuho	Buy
Jan-05-23	Initiated	BofA Securities	Buy
May-25-22	Initiated	Citigroup	Buy
Apr-01-22	Downgrade	Goldman	Buy → Neutral

View All

Amylyx Pharmaceuticals Inc Stock (AMLX) Latest News

May 25, 2026

Amylyx gets FDA fast track status for ALS treatment - MSN

May 25, 2026

May 24, 2026

Amylyx Stock: Why the Full Pipeline Story Matters - MarketBeat

May 24, 2026

May 23, 2026

Guggenheim Initiates Coverage of Amylyx Pharmaceuticals (AMLX) with Buy Recommendation - MSN

May 23, 2026

Amylyx Pharmaceuticals eyes phase 3 AVEXITIDE readout as 2027 launch comes into focus - MSN

May 23, 2026

May 22, 2026

AMLX Stock Price, Quote & Chart | AMYLYX PHARMACEUTICALS INC (NASDAQ:AMLX) - ChartMill

May 22, 2026

May 20, 2026

Amylyx Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Officer FRATES JAMES M - Moomoo

May 20, 2026